Dr. Nagy conducted research to find a novel therapy for high-risk neuroblastoma.
The study focused on therapeutic targeting of ALYREF-mediated MYCN turnover in high risk neuroblastoma. The goal of the study was to develop a therapeutic strategy that target the crosstalk between chromosome 17 and MYCN in neuroblastoma.
This project was taken over by Dr. Kevin Wang as Dr. Nagy moved to the United States. Dr. Kevin Wang obtained his PhD from Lens Research Laboratory at the University of Sydney in 2008 and joined the Children’s Cancer Institute in 2021.
More Information
Therapeutic targeting of ALYREF-mediated MYCN turnover in high risk neuroblastoma
